Search
Quinupristin
go.drugbank.com/drugs/DB01369ApprovedThe combination of the two components acts synergistically and is more effective in vitro than each component alone. … Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Ephedrine
go.drugbank.com/drugs/DB01364ApprovedInvestigationalEphedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. … [A193701,A193704,L12975] Ephedrine was granted a type 7 FDA Approval on 29 April 2016.[L12975]
Synonyms: L-Ephedrine, L(−)-ephedrineMixtures: COPHADYL-E COUGH LINCTUS, ColdaeWon Cold AOdevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigational[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigational[A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized … Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.
Belimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigationalIt is produced by recombinant DNA technology in a murine cell (NS0) expression system. … [L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years.
Xanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigational[L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity … [A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigational[L11935] Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. … In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality.
Atacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797,L63928] The approval is conditional on a proven reduction of proteinuria in the Origin 3 trial, which is evaluating whether the atacicept slows long-term kidney function decline. … factor (BAFF) and A Proliferation Inducing Ligand (APRIL).
Voxelotor
go.drugbank.com/drugs/DB14975ApprovedThis is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition
Potassium perchlorate
go.drugbank.com/drugs/DB09418ApprovedWithdrawnPotassium perchlorate is an inorganic salt with the chemical formula KClO4. It is a strong oxidizer with the lowest solubility of the alkali metal perchlorates. … The therapeutic use of potassium perchlorate in thyroid disorders has been ceased due to a high risk for developing aplastic anemia and nephrotic syndrome [L2364].